Search results for "Injection"

showing 10 items of 920 documents

Role of central oxytocin in the inhibition by endotoxin of distension-stimulated gastric acid secretion

2000

The gastric acid hyposecretory state associated with endotoxemia is mediated by a nervous reflex involving the central nervous system. The aim of the present study was to analyse the central effects of different peptides on distension-stimulated gastric acid secretion and the endogenous role of such peptides on the hyposecretory effects of endotoxin. The effect of an intracisternal (i.c.) administration of oxytocin, vasopressin, corticotropin releasing factor (CRF), bombesin, somatostatin and the opioid receptor agonist BW443C or an intravenous (i.v.) injection of a small dose of endotoxin on distension-stimulated gastric acid secretion was studied in the continuously perfused stomach of an…

MaleVasopressinendotoxinCorticotropin-Releasing HormonevasopressinNarcotic AntagonistsGastric DilatationOxytocinchemistry.chemical_compoundVasoconstrictor AgentsReceptorChemistryStomachBombesincorticotropin-releasing factorGeneral MedicineSomatostatinmedicine.anatomical_structurebombesinReceptors Oxytocingastric acid secretionBombesinFemaleSomatostatingastric distensionOligopeptidesAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsmedicine.drugmedicine.medical_specialtyVasopressinsReceptors Corticotropin-Releasing HormoneGastric AcidAdrenergic AgentsInternal medicineoxytocinmedicineAnimalsRats WistarInjections IntraventricularPharmacologyDose-Response Relationship Drugcentral nervous systemOxytocin receptorEndotoxemiaHormonesRatsEndotoxinsReceptors BombesinEndocrinologyOxytocinGastric MucosaGastric acid
researchProduct

Intra-articular hyaluronic acid injections for hip osteoarthritis

2018

Although viscosupplementation has been used in the past few years both for knee and hip osteoarthritis (OA), the number of intra-articular injections and the interval between doses still remains an undetermined subject. The aim of this open retrospective study was to evaluate the clinical and functional outcome in patients with mild-moderate hip OA treated with a course of 1, 2 or 3 Hyaluronic Acid (HA) intra-articular injections. Ninety-six patients were included: 19 patients received only one injection, 24 received two injections, and 44 received three injections. Age, sex, VAS for pain and WOMAC score before each intra-articular injection, number of intra-articular injections, reasons fo…

MaleViscosupplementationviscosupplementaton knee and hip ostoarthritis intrarticular injections hyaluronic acidTreatment OutcomeArthroplasty Replacement HipSettore MED/34 - Medicina Fisica E RiabilitativaHumansPainFemaleHyaluronic AcidOsteoarthritis HipInjections Intra-ArticularRetrospective Studies
researchProduct

Is Ranibizumab effective in stopping the loss of vision for Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study

2010

Aim To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM). Design Prospective, multicentre, interventional case series. Methods 40 eyes of 39 consecutive patients with PM and CNV were treated with ‘on demand’ intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results Mean age was 53±13 years and mean refractive error –13.5±6.5 D. Median follow-up was 13.3±2 (range 12–18) months. Fifteen eyes (37.5%) had previou…

MaleVisual Acuity/drug effectsRefractive errorgenetic structuresEye diseaseVisual AcuityVision disorderProspective StudiesFluorescein AngiographyMedicine(all)Neovascularisationmedicine.diagnostic_testAntibodies MonoclonalDrugsDiabetic retinopathyMiddle AgedFluorescein angiographySensory SystemsChoroidal neovascularizationmedicine.anatomical_structureMyopia DegenerativeIntravitreal InjectionsFemaleMyopia Degenerative/complicationsmedicine.symptomTomography Optical Coherencemedicine.drugAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedAntibodies Monoclonal/administration & dosageCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansAgedbusiness.industryChoroidChoroidal Neovascularization/drug therapyOff-Label Usemedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyChoroidsense organsRanibizumabaged 80 and overbusinessFollow-Up Studies
researchProduct

Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome

2015

Purpose To report the incidence and characteristics of endophthalmitis after intravitreal injections of anti–vascular endothelial growth factor agents or corticosteroids and to describe the clinical and bacteriologic characteristics, management, and outcome of these eyes with acute endophthalmitis in France. Design Retrospective, nationwide multicenter case series. Methods From January 2, 2008 to June 30, 2013, a total of 316 576 intravitreal injections from 25 French ophthalmic centers were included. For each center, the number of intravitreal injections was determined using billing codes and the injection protocol was recorded. A registry and hospital records were reviewed to identify pat…

MaleVisual acuityfactor agentsVisual AcuityAngiogenesis InhibitorsEye Infections BacterialEndophthalmitisAntisepticRisk Factorscausative organismsrisk-factorsAged 80 and overEndophthalmitis[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyIncidence (epidemiology)IncidenceMiddle AgedAnti-Bacterial Agents[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansIntravitreal InjectionsFemaleFrancePresentation (obstetrics)medicine.symptommetaanalysisAdultmedicine.medical_specialtymacular degenerationmedicine.drug_classRetinal DiseasesmedicineHumansranibizumab[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansGlucocorticoidsAgedRetrospective Studiesocular surfaceBacteriabusiness.industryRetrospective cohort studyantibiotic-prophylaxisEye infectionmedicine.diseaseConfidence intervalSurgeryVitreous BodyOphthalmologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyoperating-roomendothelial growth-factor
researchProduct

Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

2019

Purpose: To analyse the effects of intravitreal dexamethasone implant (DEX) in patients with diabetic macular oedema (DME) unresponsive to ranibizumab treatment, in relation to the inflammatory optical coherence tomography (OCT) retinal features, subfoveal neuroretinal detachment (SND) and hyperreflective retinal spots (HRS). Methods: Patients with DME poorly responsive to three injections of ranibizumab were treated with DEX. Best-corrected visual acuity (BCVA) and central macula thickness (CMT, measured by Spectralis SD-OCT) were assessed at baseline and at 1, 3, and 6 months. Results: Overall, 44 eyes were included in the study. In the whole group, mean BCVA (baseline 51.5 ± 8.3 letters)…

MaleVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsDrug Implantchemistry.chemical_compound0302 clinical medicineGlucocorticoidMacula LuteaProspective StudiesFluorescein AngiographyProspective cohort studyTomographyDrug Implantsmedicine.diagnostic_testGeneral MedicineDiabetic retinopathyDrug ToleranceFluorescein angiographyTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalemedicine.symptomDrugTomography Optical Coherencemedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyFundus Oculibest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography Optical Coherence; Treatment Outcome; Visual AcuitydexamethasoneMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesOphthalmologyRanibizumabmedicineHumansMacular edemaGlucocorticoidsDexamethasoneAgedbest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship; Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography; Optical Coherence; Treatment Outcome; Visual Acuityoptical coherence tomographyDiabetic RetinopathyDose-Response Relationship Drugbusiness.industryIntravitreal InjectionRetinalmedicine.diseaseeye diseasesOphthalmologyProspective StudiechemistryOptical Coherence030221 ophthalmology & optometrysense organsRanibizumabbusinessdiabetes retinopathy030217 neurology & neurosurgerybest-corrected visual acuityFollow-Up Studies
researchProduct

DEXAMETHASONE INTRAVITREAL IMPLANT VS RANIBIZUMAB IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRACHYTHERAPY FOR CHOROIDAL MELANOMA

2017

PURPOSE To evaluate the efficacy of an intravitreal dexamethasone (Dex) implant 0.7 mg compared with intravitreal ranibizumab (Ra) for the treatment of radiation maculopathy with macular edema secondary to plaque brachytherapy in choroidal melanoma. METHODS Eight patients were treated with intravitreal Ra, and eight patients received the Dex intravitreal implant. Visual acuity and foveal thickness were evaluated using spectral domain optical coherence tomography. RESULTS The mean calculated irradiation to the fovea and mean times from brachytherapy to maculopathy development did not differ significantly between groups. In the Ra group, a mean 7.8 ± 3.9 injections were given and the mean fol…

MaleVisual acuitygenetic structuresmedicine.medical_treatmentBrachytherapyOcular hypertensionAngiogenesis InhibitorsDrug Implant0302 clinical medicineGlucocorticoidDexamethasone Intravitreal ImplantRadiation InjurieMelanomaDrug ImplantsChoroid NeoplasmsGeneral MedicineMiddle AgedIntravitreal InjectionsDrug Therapy CombinationFemalemedicine.symptommedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyBrachytherapydexamethasone03 medical and health sciencesradiation maculopathyOphthalmologyRanibizumabmedicineHumanschoroidal melanomaRadiation InjuriesGlucocorticoidsMacular edemaDexamethasoneAgedRetrospective Studiesmacular edemabusiness.industryIntravitreal Injectionmedicine.diseaseeye diseasesOphthalmology030221 ophthalmology & optometryMaculopathyRanibizumabbusinessChoroid Neoplasm030217 neurology & neurosurgery
researchProduct

Anesthetic efficacy of ketamine-diazepam, ketamine-xylazine, and ketamine-acepromazine in Caspian Pond turtles (

2017

Objectives: The objective of this study was to assess the efficacy of different anesthetic drug combinations on the Caspian Pond turtles (Mauremys caspica). Subjects and Methods: Three groups of the Caspian Pond turtles (n = 6) were anesthetized with three different drug combinations. Initially, a pilot study was conducted to determine the best drug doses for the anesthetization of the turtles, and according to these results, ketamine–diazepam (120 mg/kg ketamine hydrochloride [5%] and 2 mg/kg diazepam [5%]), ketamine–acepromazine (120 mg/kg ketamine hydrochloride [5%] and 1 mg/kg acepromazine [1%]), and ketamine–xylazine (120 mg/kg ketamine hydrochloride [5%] and 1 mg/kg xylazine [2%]) wer…

MaleXylazineDiazepamTime FactorsDose-Response Relationship DrugketamineShort CommunicationPilot ProjectsInjections IntramuscularTurtlesSex FactorsAnesthesia Recovery PeriodAnimalsFemaleAcepromazineAnestheticsMauremys caspicaIndian journal of pharmacology
researchProduct

Anesthetic efficacy of ketamine-diazepam, ketamine-xylazine, and ketamine-acepromazine in Caspian Pond turtles (Mauremys caspica)

2017

Objectives: The objective of this study was to assess the efficacy of different anesthetic drug combinations on the Caspian Pond turtles (Mauremys caspica). Subjects and Methods: Three groups of the Caspian Pond turtles (n = 6) were anesthetized with three different drug combinations. Initially, a pilot study was conducted to determine the best drug doses for the anesthetization of the turtles, and according to these results, ketamine-diazepam (120 mg/kg ketamine hydrochloride [5%] and 2 mg/kg diazepam [5%]), ketamine-acepromazine (120 mg/kg ketamine hydrochloride [5%] and 1 mg/kg acepromazine [1%]), and ketamine-xylazine (120 mg/kg ketamine hydrochloride [5%] and 1 mg/kg xylazine [2%]) wer…

MaleXylazinePharmacologyDiazepamketamineDose-Response Relationship DrugTime FactorAnimalAnestheticSex FactorInjections IntramuscularTurtleAnesthesia Recovery PeriodFemalePilot ProjectPharmacology (medical)Mauremys caspicaAcepromazine
researchProduct

Origin and ploidy of multipronuclear zygotes

2000

Recently, several authors have proposed strategies for correction of triploidy based on the removal of the extra pronucleus at the zygote stage. In the present bioassay, the following were analysed: (1) the different factors that can induce the formation of multipronuclear zygotes in mammals; (2) the different morphological patterns established according to the number of pronuclei and polar bodies that can be observed at the zygote stage and used to distinguish the origin of multipronuclear zygotes; and (3) the pattern of chromosomal segregation during the first mitotic division and ploidy status of the resulting preim-plantation embryos. Such an analysis shows that the morphological crite…

MaleZygoteReproductive technologyDigynyBiologyPolyploidyPolar bodyEndocrinologyMeiosisGeneticsAnimalsHumansSperm Injections IntracytoplasmicMolecular BiologyCell NucleusCryopreservationSperm-Ovum InteractionsGeneticsZygotePronucleusAge FactorsEmbryoSpermatozoaCell biologyMeiosisReproductive MedicineOocytesFemaleAnimal Science and ZoologyPloidyDevelopmental BiologyBiotechnologyReproduction, Fertility and Development
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct